Lastly the efficacy of DR17 in inhibiting growth of graft in both 22Rv1 and CaP2 xenograft model implies that this three drug combination delivered by micelle can target PTEN-mutated prostate cancer as well as castration-resistant prostate cancer. Here, PTEN is linked to prostate carcinoma.